title: Dopamine D(2)-class receptor supersensitivity as reflected in Ca2+ current modulation in neostriatal neurons.
abstract: The loss of dopaminergic neurons followed by dopamine (DA) depletion in the neostriatum is a hallmark of Parkinson's disease. Among other changes, DA D(2)-receptor class (D(2)R-class) supersensitivity is a result of striatal DA depletion. Pharmacological, biochemical and behavioral data have documented this phenomenon, but clear electrophysiological-functional correlates are still lacking. This work describes an electrophysiological correlate of D(2)R-class supersensitivity in DA-depleted striata after unilateral 6-hydroxydopamine (6-OHDA) lesions in the rat substantia nigra compacta (SNc). Ca2+ current modulation mediated by D(2)R-class activation reflected an altered sensitivity. Thus, while the concentration-response relationship (C-R plot) from control striata was better fit with a two sites model, the C-R plot obtained from DA-depleted striata was better fit by a three sites model, exhibited a considerable leftward shift, and presented an increased maximal response. Because Ca2+ current modulation by D(2)R-class activation is involved in the control of spiny neurons excitability and their synaptic GABA release, the present findings may help to explain several functional changes found in the striatal circuitry after dopaminergic denervation.
authors.affiliation: Instituto de Fisiología Celular-Neurociencias, Universidad Nacional Autónoma de México.
authors.forename: G A
authors.initials: GA
authors.lastname: Prieto
authors.forename: A
authors.initials: A
authors.lastname: Perez-Burgos
authors.forename: T
authors.initials: T
authors.lastname: Fiordelisio
authors.forename: H
authors.initials: H
authors.lastname: Salgado
authors.forename: E
authors.initials: E
authors.lastname: Galarraga
authors.forename: R
authors.initials: R
authors.lastname: Drucker-Colin
authors.forename: J
authors.initials: J
authors.lastname: Bargas
mesh_terms: D018663:Adrenergic Agents / Q000633:toxicity; D000818:Animals; D002118:Calcium / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000494:pharmacology; D015220:Calcium Channels / Q000378:metabolism; D003342:Corpus Striatum / Q000187:drug effects / Q000502:physiology*; D004298:Dopamine / Q000378:metabolism; D008297:Male; D008564:Membrane Potentials; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D016627:Oxidopamine / Q000633:toxicity; D051381:Rats; D017208:Rats, Wistar; D017448:Receptors, Dopamine D2 / Q000819:agonists / Q000378:metabolism*; D013378:Substantia Nigra / Q000187:drug effects / Q000503:physiopathology
chemical_list: D018663:Adrenergic Agents; D002121:Calcium Channel Blockers; D015220:Calcium Channels; D017448:Receptors, Dopamine D2; D016627:Oxidopamine; D002118:Calcium; D004298:Dopamine